ORGANIC
LETTERS
2003
Vol. 5, No. 23
4253-4256
Synthesis of 3-Aminochroman
Derivatives by Radical Cyclization
Gre´goire Pave´,† Ste´phanie Usse-Versluys,† Marie-Claude Viaud-Massuard,‡ and
,†
Ge´rald Guillaumet*
Institut de Chimie Organique et Analytique, UMR CNRS 6005, UniVersite´ d’Orle´ans,
BP 6759, 45067 Orle´ans Cedex 2, France, and Groupe de Recherche en Chimie
He´te´rocyclique et The´rapeutique, EA 3247, UFR Sciences Pharmaceutiques,
UniVersite´ de Tours, 31 aVenue Monge, 37200 Tours, France
gerald.guillaumet@uniV-orleans.fr
Received July 17, 2003
ABSTRACT
Enantiomerically pure 5-acetyl-3-amino-3,4-dihydro-2H-1-benzopyran and methyl 3-amino-3,4-dihydro-2H-1-benzopyran-5-carboxylate were
successfully synthesized starting from D- or L-serine. The formation of the benzopyran ring involved a radical cyclization step. The enantiomeric
purities of the final aminochroman derivatives were determined by capillary electrophoresis using â-cyclodextrins as a chiral selector.
Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter
of the central nervous system. The identification of multiple
serotonin receptor subtypes has triggered the discovery of
new drugs that alter 5-HT neurotransmission.1 Due to its
neuroprotective properties2 and its key role in many (patho)
physiological processes,3 the 5-HT1A receptor is a major
target for neurobiological research and drug development.
The 5-HT7 receptor is the most recent addition to the
serotonin subfamily of G-protein-coupled receptors.4 At the
present time, the biological functions of this receptor are still
unknown. Recent reports suggest that it could be involved
in the control of circadian rhythms5 or in the etiology of
depression.6 Due to the role of 5-HT1A and 5-HT7 receptors
in anxiety and depression, the synthesis of agonists appears
to be very attractive. In our laboratory, previous works7 have
led to new potential therapeutic agents that demonstrated
promising affinity and high selectivity toward the 5-HT1A
and 5-HT7 receptors. For example, compound 1a (Figure 1)
showed 0.3 and 3.9 nmol affinities toward these receptors,
respectively.7c
(5) (a) Bard, J. A.; Zgombick, J.; Adham, N.; Vaysee, P.; Branchek, T.
A.; Weinshank, R. L. J. Biol. Chem. 1993, 268, 23422. Ruat, M.; Traiffort,
E.; Leurs, R.; Tardivel-Lacombe, J.; Diaz, J.; Arrang, J.-M.; Schwartz, J.
C. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 8547. (c) To, Z. P.; Bonhaus,
D. W.; Eglen, R. M.; Jakeman, L. B. Br. J. Pharm. 1995, 115, 107. (d)
Shen, Y.; Monsma, F. J.; Metcalf, M. A.; Jose, P. A.; Hamblin, M. W.;
Sibley, D. R. J. Biol. Chem. 1993, 268, 18200.
(6) Lovenberg, T. W.; Baron, B. M.; deLecea, L.; Miller, J. O.; Prosser,
R. A.; Rea, M. A.; Foye, P. E.; Rucke, M.; Slone, A. L.; Siegel, B. W.;
Danielson, P. E.; Sutcliffe, J. G.; Erlander, M. G. Neuron 1993, 11, 449.
(7) (a) Podona, T.; Guardiola-Lemaˆıtre, B.; Caignard, D. H.; Adam, G.;
Pfeiffer, B.; Renard, P.; Guillaumet, G. J. Med. Chem. 1994, 37, 1779. (b)
Comoy, C.; Marot, C.; Podona, T.; Baudin, M. L.; Morin-Allory, L.;
Guillaumet, G.; Pfeiffer, B.; Caignard, D. H.; Renard, P.; Rettori, M. C.;
Adam, G.; Guardiola-Lemaˆıtre, B. J. Med. Chem. 1996, 39, 4285. (c) Rezaie,
R.; Joseph, B.; Bremner, J. B.; Delagrange, P.; Kopp, C.; Misslin, R.;
Pfeiffer, B.; Renard, P.; Guillaumet, G. J. Pharm. Pharmacol. 2001, 53,
959-968. (d) Usse, S.; Guillaumet, G.; Viaud, M. C. J. Org. Chem. 2000,
65, 914. (e) Usse, S.; Pave´, G.; Guillaumet, G.; Viaud-Massuard, M.-C.
Tetrahedron: Asymmetry 2001, 12, 1689. (f) Pave´, G.; Le´ger, J.-M.; Jarry,
C.; Viaud-Massuard, M.-C.; Guillaumet, G. J. Org. Chem. 2003, 68, 1401.
† Universite´ d’Orle´ans.
‡ Universite´ de Tours.
(1) (a) Baumgarten, H. G.; Go¨thert, M. Serotoninergic Neurons and
5-HAT Receptors in the CNS; Springer-Verlag: Berlin, 1997; Vol. 129.
(b) Martin, G. R.; Eglen, R. M.; Hoyer, D.; Hamblin, M. W.; Yocca, F.
Annals of the New York Academy of Sciences; New York Academy of
Sciences: New York, 1998; Vol. 861.
(2) (a) Alessandri, B.; Tsuchida, E.; Bullock, R. M. Brain Res. 1999,
845, 232. (b) Kamei, K.; Maeda, N.; Ogino, R.; Koyama, M.; Nakajima,
M.; Tatsuoka, T.; Ohno, T. Inoue, T. Bioorg. Med. Chem. Lett. 2001, 11,
595. (c) Harkany, T.; Mulder, J.; Horvath, K. M.; Keijser, J.; van der
Meerberg, E. K.; Nyakas, C.; Luiten, P. G. M. Neuroscience 2001, 108,
629.
(3) (a) Olivier, B.; van Wijngaarden, I.; Soudjin, W. Serotonin Receptors
and their Ligands; Elsevier: Amsterdam, 1997. (b) Olivier, B.; van
Wijngaarden, I. Prog. Drug. Res. 1999, 52, 103. (c) Lo´pez-Rodriguez, M.
L.; Ayala, D.; Benhamu´, B.; Morcillo, M. J.; Viso, A. Curr. Med. Chem.
2002, 9, 443.
(4) Hoyer, D.; Hannon, J. P.; Martin, G. R. Pharmacol. Biochem. BehaV.
2002, 71, 533.
10.1021/ol0353215 CCC: $25.00 © 2003 American Chemical Society
Published on Web 10/16/2003